Business
MediWound Expands Global Reach with Marketing Approval of NexoBrid® in Australia
MediWound Expands Global Reach with Marketing Approval of NexoBrid® in Australia TGA Approves NexoBrid® for Adults and Children; Manufacturing Readiness Positions MediWound for 2025 Launch and Asia-Pacific Expansion YAVNE, Israel, September 25, 2025 -- MediWound Ltd. (Nasdaq: MDWD), a global leader in next-generation enzymatic therapeutics for tissue repair, today announced that Australia’s Therapeutic Goods Administration (TGA) has granted marketing authorization for NexoBrid®, the Company’s in
About this update from Mediwound Ltd.
[{"type":"image","alt":"MediWound Ltd.","displaySize":"","headline":null,"caption":"MediWound Ltd.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":113,"url":"https://media.zenfs.com/en/globenewswire.com/ad5b557425c9c98b1d6e3e31c57b3159"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/lMBSATvDCuA9PnawJVvewQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE1ODtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/ad5b557425c9c98b1d6e3e31c57b3159","width":300,"height":113}},"lazy":false},{"type":"text","content":"","length":0,"tagName":"p"},{"type":"text","content":"MediWound Expands Global Reach with Marketing Approval of NexoBrid® in Australia ","length":80,"tagName":"p"},{"type":"text","content":"TGA Approves NexoBrid® for Adults and Children; Manufacturing Readiness Positions MediWound for 2025 Launch and Asia-Pacific Expansion","length":134,"tagName":"p"},{"type":"text","content":"YAVNE, Israel, September 25, 2025 -- MediWound Ltd. (Nasdaq: MDWD), a global leader in next-generation enzymatic therapeutics for tissue repair, today announced that Australia’s Therapeutic Goods Administration (TGA) has granted marketing authorization for NexoBrid®, the Company’s innovative enzymatic therapy for the removal of eschar in both adult and pediatric patients with deep partial- and full-thickness thermal burns.","length":426,"tagName":"p"},{"type":"text","content":"With this approval, NexoBrid is now authorized in 45 countries worldwide, reflecting its growing recognition as a new standard of care in burn management. MediWound’s exclusive partner in Australia, Balance Medical, expects to initiate commercial launch in the fourth quarter of 2025.","length":284,"tagName":"p"},{"type":"text","content":"MediWound’s manufacturing expansion, on track for completion by year-end 2025, will support this launch and future global demand.","length":129,"tagName":"p"},{"type":"text","content":"“The TGA approval of NexoBrid marks another important step in expanding access to innovative, non-surgical burn care,” said Ofer Gonen, Chief Executive Officer of MediWound. “Together with our partner Balance Medical, we will ensure that burn centers across Australia have access to this therapy. Importantly, this milestone also opens the door to the broader Asia-Pacific region, where we see growing demand for advanced wound and burn treatments.”","length":449...